Translational Solutions for Every Stage of Care
Our multimodal AI diagnostics platform bridges clinical precision, patient-centered empowerment, and large-scale academic research to redefine how neurodegenerative diseases are intercepted.
For Clinicians & Physicians
Equipping primary care practitioners, neurologists, and memory clinics with sub-second ocular phenotyping and explainable multimodal AI to diagnose early cognitive decline long before macroscopic brain atrophy.
Point-of-Care Integration
Seamlessly deploys into outpatient clinics and ophthalmologic networks. Replaces costly lumbar punctures and radioactive amyloid PET imaging with rapid, non-invasive optical scanning.
Quantitative Biomarker Dashboard
Delivers standardized, explainable scoring aligned with the clinical ATN(V) framework—mapping retinal microvascular alterations, drusen phenotyping, and acoustic cadences against disease trajectories.
Early Therapeutic Interception
Enables timely eligibility assessment for next-generation disease-modifying therapies (e.g., anti-amyloid monoclonals) within the critical pre-symptomatic prodromal therapeutic window.
For Patients & Caregivers
Replacing fear and prolonged diagnostic uncertainty with dignity, clarity, and compassionate, stress-free testing. We provide actionable clarity and evidence-based non-pharmacological care pathways.
Painless & Gentle Screening
No needles, no radiation, and no exhausting multi-hour psychometric batteries. Our retinal imaging feels just like a routine eye examination at your optometrist.
Actionable Clarity Early On
A timely diagnosis restores personal agency. It enables individuals and families to take proactive measures, adapt lifestyle parameters, and prepare for the future with security.
Resource-Preserving Therapies
Backed by our scientific advisory and evidence-based concepts like the MAKS therapy (motor, practical, cognitive, and social stimulation), stabilizing daily capabilities and family well-being.
For Research & Clinical Trials
Accelerating neurodegenerative drug development with ultra-precise, cost-effective patient cohort stratification, high-frequency longitudinal monitoring, and multimodal data integration.
Cohort Enrichment & Pre-Screening
Dramatically reduces clinical trial screen failure rates by triaging amyloid-positive and tau-positive candidate cohorts before confirmatory PET or CSF confirmation.
High-Density Longitudinal Tracking
Monitor therapeutic efficacy and microstructural neurovascular changes at short intervals without radiation cumulative limits or patient burden.
92-Band Hyperspectral Data Cubes
Direct export of calibrated spatial-spectral curves, acoustic phonetic spectra, and cognitive response micro-timings for machine learning researchers.